Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Postgraduate Medicine|December 19, 2015
Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic painLouise Taber, Shau Yu Lynch, Ellie He, et al.
Journal of Opioid Management|August 28, 2015
12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic painWarren Wen, Louise Taber, Shau Yu Lynch, et al.
Expert Opinion on Pharmacotherapy|June 27, 2015
A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back painWarren Wen, Steve Sitar, Shau Yu Lynch, et al.
Geriatric Nursing (New York, N.Y.)|August 10, 2016
Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic painKathleen Broglio, Joseph Pergolizzi, Maribeth Kowalski, et al.
Pain Practice : the Official Journal of World Institute of Pain|June 19, 2016
Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic PainKathleen Broglio, Joseph Pergolizzi, Maribeth Kowalski, et al.
Expert Opinion on Drug Safety|March 20, 2013
Application site adverse events associated with the buprenorphine transdermal system: a pooled analysisWarren Wen, Shau Yu Lynch, Catherine Munera, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
ABBV-552 in patients with mild Alzheimer's disease: a randomized phase IIb trialShau Yu Lynch, Jia Jia, Nick Miles, et al.
Expert Opinion on Pharmacotherapy|February 5, 2013
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back painKate Miller, Aaron Yarlas, Warren Wen, et al.
Pain Physician|January 11, 2017
Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical StudiesKathleen Campbell, J Walter Kutz, Angela Shoup, et al.
Clinical Therapeutics|January 11, 2016
Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent PropertiesRam P Kapil, Alessandra Cipriano, Warren Wen, et al.
Pageof 2